Not much news to report from the 14th annual Myeloma Workshop in Kyoto, Japan. I know there are a large number of poster study results being displayed, along with oral presentations, too. But I’m not there and I don’t believe anyone is covering the event from the Myeloma Beacon, either. Regardless, I would like to take a different tact and examine important ongoing research at Dartmouth College.
If you have been doing any reading at all about the latest and most promising cancer therapies lately, you have undoubtedly read about “T-cells.” My science background is sketchy at best, so sometimes I have trouble following the more technical aspects of some study results. That’s why I found this article to be so fascinating. It is written for you and me! I recommend you read, Improving immunity against multiple myeloma, By Lauren Ware.
Apparently, T cells with certain markers are more effective than other lymphocytes in combating myeloma. Researchers identified the marker(s), manipulated cells from patient’s blood and then re-infused-it along with an immune-boosting molecule. One of the unusual things about this therapy is it would be applied at the time a patient undergoes an auto (using their own cells) stem cell transplant. What a great idea!
Results look promising, but it is still not known how much these modified, super T cells might help. From what I read, sounds like Dartmouth researchers are on the right track.
Dartmouth’s BMT program director, Dr. Kenneth Meehan, closed that article by saying, “This is really an example of bench to bedside, back to bench and to bedside again.”
Ingenuous, exciting and hopeful! I’m convinced that therapies like this will some day allow me and my fellow myeloma patients to live longer–a lot longer.
Feel good and keep smiling! Pat